Have a feature idea you'd love to see implemented?
Let us know!
CALC CalciMedica Inc
Price (delayed)
$3.45
Market cap
$46.51M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.08
Enterprise value
$37.36M
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102,
Highlights
The EPS has soared by 95% YoY and by 23% from the previous quarter
CALC's net income has soared by 53% YoY but it is down by 8% QoQ
CALC's equity is down by 35% since the previous quarter and by 26% year-on-year
The quick ratio has contracted by 21% from the previous quarter and by 2.5% YoY
Key stats
What are the main financial stats of CALC
Market
Valuations
Earnings
Shares outstanding
13.48M
Market cap
$46.51M
Enterprise value
$37.36M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.11
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$13.59M
EBITDA
-$13.53M
Free cash flow
-$19.79M
Per share
Balance sheet
Liquidity
EPS
-$1.08
Free cash flow per share
-$1.78
Book value per share
$0.84
Revenue per share
$0
TBVPS
$1.46
Total assets
$16.21M
Total liabilities
$7.18M
Debt
$0
Equity
$9.03M
Working capital
$11.9M
Debt to equity
0
Current ratio
4.15
Quick ratio
3.86
Net debt/EBITDA
0.68
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-71%
Return on equity
-112.6%
Return on invested capital
-159.5%
Return on capital employed
-109.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CALC stock price
How has the CalciMedica stock price performed over time
Intraday
0%
1 week
2.37%
1 month
-16.26%
1 year
11.65%
YTD
20.63%
QTD
-22.12%
Financial performance
How have CalciMedica's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$22.35M
Net income
-$13.59M
Gross margin
N/A
Net margin
N/A
CALC's net income has soared by 53% YoY but it is down by 8% QoQ
CALC's operating income is up by 39% year-on-year but it is down by 4.2% since the previous quarter
Growth
What is CalciMedica's growth rate over time
Valuation
What is CalciMedica stock price valuation
P/E
N/A
P/B
4.11
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 95% YoY and by 23% from the previous quarter
CALC's price to book (P/B) is 116% higher than its 5-year quarterly average of 1.9 and 28% higher than its last 4 quarters average of 3.2
CALC's equity is down by 35% since the previous quarter and by 26% year-on-year
Efficiency
How efficient is CalciMedica business performance
CalciMedica's return on assets has surged by 56% YoY but it has decreased by 7% QoQ
The return on equity has declined by 15% since the previous quarter
Dividends
What is CALC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CALC.
Financial health
How did CalciMedica financials performed over time
The total assets is 126% greater than the total liabilities
The company's total liabilities has surged by 95% YoY
The total assets has declined by 23% since the previous quarter but it has grown by 2.3% year-on-year
The debt is 100% smaller than the equity
CALC's equity is down by 35% since the previous quarter and by 26% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.